Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 1:17 PM
Ignite Modification Date: 2025-12-25 @ 12:25 PM
NCT ID: NCT02531295
Description: Systematic assessment through detailed questionnaires and principal investigator physical exam assessment was conducted at each visit.
Frequency Threshold: 0
Time Frame: The total duration of the study was approximately 10 months from May 15, 2019 to March 19, 2020. Each participant was assessed for 31 days during the duration of their enrollment in the study. No severe adverse events occurred during the trial. There were no discontinuations or participants who left the trial early.
Study: NCT02531295
Study Brief: Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Placebo 1g Per Day x 2 Days Study participants will be given 1 g placebo prepared as tea for a total of 2 consecutive daily doses. 0 None 0 0 0 0 View
Placebo 1g Per Day x 3 Days Study participants will be given 1 g of placebo prepared as tea for a total of 3 consecutive daily doses. 0 None 0 2 0 2 View
Placebo 1g Per Day x 1 Day Study participants will be given 1 g of placebo prepared as tea for a total of 1 daily dose. 0 None 0 0 0 0 View
Kansui 1g Per Day x 1 Day Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 1 daily dose. Euphorbia kansui extract powder prepared as tea: 1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily 0 None 0 2 0 2 View
Kansui 1g Per Day x 2 Days Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 2 consecutive daily doses. Euphorbia kansui extract powder prepared as tea: 1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily 0 None 0 0 0 0 View
Kansui 1g Per Day x 3 Days Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 3 consecutive daily doses. Euphorbia kansui extract powder prepared as tea: 1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily 0 None 0 1 0 1 View
Serious Events(If Any):
Other Events(If Any):